BioLineRx and Hemispherian Present Preclinical GLIX1 Data at ESMO 2026
The companies reported preclinical findings of synergy between GLIX1 and PARP inhibitors in HR-proficient ovarian cancer. The data included multiple cell lines and a patient-derived xenograft model.